1. Home
  2. IPSC vs LOAN Comparison

IPSC vs LOAN Comparison

Compare IPSC & LOAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IPSC
  • LOAN
  • Stock Information
  • Founded
  • IPSC 2019
  • LOAN 1989
  • Country
  • IPSC United States
  • LOAN United States
  • Employees
  • IPSC N/A
  • LOAN N/A
  • Industry
  • IPSC Medicinal Chemicals and Botanical Products
  • LOAN Real Estate Investment Trusts
  • Sector
  • IPSC Health Care
  • LOAN Real Estate
  • Exchange
  • IPSC Nasdaq
  • LOAN Nasdaq
  • Market Cap
  • IPSC 49.6M
  • LOAN 58.1M
  • IPO Year
  • IPSC 2021
  • LOAN 1999
  • Fundamental
  • Price
  • IPSC $0.56
  • LOAN $5.53
  • Analyst Decision
  • IPSC Strong Buy
  • LOAN
  • Analyst Count
  • IPSC 5
  • LOAN 0
  • Target Price
  • IPSC $3.33
  • LOAN N/A
  • AVG Volume (30 Days)
  • IPSC 1.2M
  • LOAN 13.5K
  • Earning Date
  • IPSC 08-07-2025
  • LOAN 07-21-2025
  • Dividend Yield
  • IPSC N/A
  • LOAN 8.26%
  • EPS Growth
  • IPSC N/A
  • LOAN N/A
  • EPS
  • IPSC N/A
  • LOAN 0.48
  • Revenue
  • IPSC $114,898,000.00
  • LOAN $7,291,468.00
  • Revenue This Year
  • IPSC $1,064.82
  • LOAN N/A
  • Revenue Next Year
  • IPSC N/A
  • LOAN $4.41
  • P/E Ratio
  • IPSC N/A
  • LOAN $11.61
  • Revenue Growth
  • IPSC 8286.72
  • LOAN N/A
  • 52 Week Low
  • IPSC $0.34
  • LOAN $4.74
  • 52 Week High
  • IPSC $3.29
  • LOAN $6.05
  • Technical
  • Relative Strength Index (RSI)
  • IPSC 46.47
  • LOAN 68.77
  • Support Level
  • IPSC $0.52
  • LOAN $5.12
  • Resistance Level
  • IPSC $0.60
  • LOAN $5.49
  • Average True Range (ATR)
  • IPSC 0.04
  • LOAN 0.09
  • MACD
  • IPSC -0.01
  • LOAN 0.03
  • Stochastic Oscillator
  • IPSC 25.19
  • LOAN 92.11

About IPSC Century Therapeutics Inc.

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

Share on Social Networks: